瑞舒伐他汀对急性冠脉综合征患者血高敏C反应蛋白及同型半胱氨酸水平的影响

Effect of Rosuvastatin on Serum High-Sensitivity C-Reactive Protein and Homocysteine in Patients with Acute Coronary Syndromes

目的探讨瑞舒伐他汀对急性冠脉综合征患者血高敏C反应蛋白(hs-CRP)及同型半胱氨酸(Hcy)水平的影响。方法将在本院治疗的60例急性冠脉综合征患者随机分为甲组和乙组,两组患者均行急性冠脉综合征常规治疗,在此基础上甲组给予瑞舒伐他汀治疗,乙组给予阿托伐他汀治疗。治疗后比较两组hs-CRP和Hcy水平。结果治疗前,甲组和乙组hs-CRP和Hcy水平比较无显著差异,治疗4周和治疗后6个月两组hs-CRP和Hcy水平较治疗前均有降低,其中甲组两项指标下降更为显著(P<0.05)。结论瑞舒伐他汀与阿托伐他汀相比在降低hs-CRP和Hcy水平方面效果更为显著。

Objective To investigate the effects of rosuvastatin on serum high-sensitivity C-reactive protein（hs-CRP） and homocysteine（Hcy） in patients with acute coronary syndromes. Methods A total of 60 patients with acute coronary syndrome were randomized into the group A and group. All subjects were treated with routine treatment. The group A received rosuvastatin. The group B was treated with atorvastatin. The levels of hs-CRP and Hcy were compared between the two groups. Results There was no significant difference in hs-CRP and Hcy levels between group A and group B before treatment（P 〉0.05）. The levels of hs-CRP and Hcy in the two groups 4 weeks and 6 months after treatment were lower than those before treatment（P 〈 0.05）, and the group A was better than group B（P 〈 0.05）. Conclusion Rosuvastatin is more effective than atorvastatin in reducing hs-CRP and Hcy levels, which is preferred in clinical practice.